
We are a team of scientists and physicians 🇩🇪🇦🇹🇫🇷🇮🇳🇺🇸 passionately working on #stemcells #organoids #cancer #pancreaticcancer @UniKlinikUlm. Est. 2009
Ulm, Germany
Joined October 2020
- Tweets69
- Following231
- Followers282
- Likes88
Visit the @Klegerlab under kleger-imos.com and consider striving your career with us ! looking forward to receive your applications for PhD and/or postdoc !
As #SarahMerz moves on to a postdoc with #DiegoBalboa at the #UniversityofHelsinki, we are excited to announce that we are recruiting the next generation of PhD students to join our successful team at #IMOS! 🌟 Let’s continue pushing the boundaries of diabetes research together!
A special thanks to #MaureenGannon for summarizing both our studies in a fantastic preview article in #CellReports titled “CUTting through the distance - A disease-relevant long-range ONECUT1 enhancer.” doi.org/10.1016/j.celrep.202… Your support is invaluable!
We also explored in vitro therapeutic options for affected patients and linked a low-frequency variant to type 2 diabetes. Excitingly, the #DanweiHuangfuLab utilized CRISPRi screening during pancreatic differentiation, confirming our findings regarding the same enhancer.Congrats!
Here, we identified a disease-causing deletion upstream of OC1 in compound heterozygosity with an OC1 mutation in an affected individual, while investigating its functional role as a cis-acting enhancer influencing OC1 expression during pancreatic development.
Building on this foundation, we're excited to announce our latest publication in #CellReports! Brilliant #SarahMerz completed her PhD with her second first authorship under the guidance of #SandraHeller, alongside #CecileJulier and me (doi.org/10.1016/j.celrep.202…).
We then discovered that OC1 coding mutations are associated with various forms of diabetes as modeled via pluripotent stem cell differentiation, details in #NatureMedicine (doi.org/10.1038/s41591-021-0…).
Our journey began with characterizing the regulatory patterns of ONECUT1 (OC1) during pancreatic lineage commitment, published in #CommunicationsBiology (doi.org/10.1038/s42003-021-0…).
🚀 I am thrilled to add another piece to the “ONECUT1 diabetes” puzzle, again with joint forces between the #JulierLab at #INSERM and the collaborative efforts #IvanCosta, the Institutes of #HumanGenetics and #TransfusionMedicine at #UlmUniversity, and other collaborators!
Kleger Lab retweeted
Freier Eintritt zur Podiumsdiskussion "Stammzellen - die Alleskönner" mit Wissenschaftler*innen zu Themen von Alterung bis Krebs. Wie ist der Stand der Forschung bei Zelltherapien? Am 15.9. in der vh Ulm. Info: gscn.org/public-resources/pu… @stadtulm @KlegerLab #stammzellen
Our commenting summary just published in Cell Stem Cell doi.org/10.1016/j.stem.2023.…
Great work by the Wang lab: there is much heterogeneity in our beloved pancreas, congrats
Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis: Cell Stem Cell cell.com/cell-stem-cell/full…
Congrats to work by the Wang lab, there is so much heterogeneity in our beloved pancreas!
Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis: Cell Stem Cell cell.com/cell-stem-cell/full…
#klegerlab at kleger-imos.com is hiring again...looking forward to get your applications
Kleger Lab retweeted
@KlegerLab Congrats Alex!
Deeply honored to receive the prestigious deutscher-krebspreis.de from @DKG_Berlin in the experimental category together with @chr_reinhardt for our work at kleger-imos.com Thanks to the entire @klegerlab @uni_ulm @UniklinikUlm and our friends and collaborators
We are recruiting again at kleger-imos.com to conduct our @organoid and @stemcell based research projects. Looking forward to receive applications. JOIN us at @IMOS
I am happy to announce that we have finished our new homepage illustrating the recently founded Institute of Molecular Oncology and Stem Cell Biology - short #imos kleger-imos.com. .






